Correlation of plasma protein carbonyls and C-reactive protein with GOLD stage progression in COPD patients

Open Respiratory Medicine Journal

Volumn 3, Issue , 2009, Pages 61-66

  Torres Ramos, Yessica D ^a   García Guillen, María L ^a   Olivares Corichi, Ivonne M ^b   Hicks, J J ^a  

^a INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

^b INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

Author keywords

Chronic obstructive pulmonary disease (COPD); Lipoperoxidation of plasma substrates (SLPS); Oxidative stress; Protein carbonyls; Reactive oxygen species (ROS)

Indexed keywords

C REACTIVE PROTEIN; MALONALDEHYDE; MYELOPEROXIDASE; REACTIVE OXYGEN METABOLITE;

AGED; ARTICLE; BLOOD SAMPLING; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVITY; FEMALE; HUMAN; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN CARBONYLATION;

EID: 77953412793     PISSN: None     EISSN: 18743064     Source Type: Journal    
DOI: 10.2174/1874306400903010061     Document Type: Article

References (27)

1. Rabe KF, Hurd S, Anzueto A, et al. Global Initiative for Chronic Obstructive Lung Disease Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176: 532-55.
2. Rahman I, Macnee W. Role of oxidants/antioxidants in smoking-induced lung diseases. Free Radic Biol Med 1996; 21: 669-81.
3. Yoshida T, Tuder RM. Pathobiology of cigarette smoke-induced chronic obstructive pulmonary disease. Physiol Rev 2007; 87: 1047-82.
4. Hicks JJ, Montes-Cortes DH, Cruz-Domínguez MP, et al. Antioxidant decrease reperfusion induced arrhythmias in myocardial infarction with ST-elevation. Front Biosci 2007; 12: 2029-37.
5. Olivares-Corichi IM, Ceballos G, Medina-Santillán R, et al. Oxidation by reactive oxygen species (ROS) alters the structure of human insulin-dependent D-glucose-C14 utilization by human adipose tissue. Front Biosci 2005; 10: 3127-31.
6. Man SF, Connet JE, Anthonisen NR, et al. C-reactive protein and mortality in mild to moderate chronic obstructive disease. Thorax 2006; 61: 849-53.
7. Allegra M, Tesoriere L, Livrea MA. Betanin inhibits the myeloperoxidase/ nitrite induced oxidation of human low-density lipoproteins. Free Radic Res 2007; 41: 335-41.
8. Andelid K, Bake B, Rak S, et al. Myeloperoxidase as a marker of increasing systemic inflammation in smokers without severe airway symptoms. Respir Med 2007; 101: 888-95.
9. Bozeman PM, Learn DB, Thomas EL, et al. Assay of the human leukocyte enzymes myeloperoxidase and eosinophil peroxidase. J Immunol Methods 1990; 126: 125-33.
10. Bernal A, Méndez JD, Rosado A. A rapid colorimetric assay for dry weight. Arch Invest Med 1981; 12: 83-8.
11. Amici A, Levine RL, Tsai L, et al. Conversion of amino acids residues in proteins and amino acid homopolymers to carbonyl derivatives by metal catalyzed reactions. J Biol Chem 1989; 264: 3341-46.
12. Lowry OH, Rosebrough NJ, Farr AL, et al. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-75.
13. Torres-Ramos YD, Sierra-Vargas MP, Olivares-Corichi IM, et al. Marcadores plasmaticos de estrés oxidante en población mexicana sana de 31 a 60 años de edad. Rev Inst Nal Enf Res 2006; 19: 206-13.
14. Celli BR, Macnee W; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932-46.
15. Siafakas NM, Vermeire P, Pride NB, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J 1995; 8: 1398-420.
16. Agusti AG, Noguera A, Sauleda J. Systemic effects of chronic obstructive disease. Eur Respir J 2003; 21: 347-60.
17. Schols AM, Wouters EF. Nutrition abnormalities and supplementation in chronic obstructive pulmonary disease. Clin Chest Med 2000; 21: 753-62.
18. Hopkinson NS, Tennant RC, Dayer MJ, et al. A prospective study of decline in fat free mass and skeletal muscle strength in chronic obstructive disease. Respir Res 2007; 13: 8-25.
19. Celli BR, Barnes PJ. Exacerbations of chronic obstructive pulmonary disease. Eur Respir J 2007; 29: 1224-38.
20. Macnee W. Oxidants and COPD. Curr Drug Targets Inflamm Allergy 2005; 4: 627-41.
21. Ravinovich RA, Bastos R, Ardite E, et al. Mitochondrial dysfunction in COPD patients with low body mass index. Eur Respir J 2007; 29: 643-50.
22. Roger T, Deans, Shanlin Fu, et al. Biochemistry and pathology of radical-mediated protein oxidation. Biochem J 1997; 324: 1-8.
23. Schneider C, Tallman KA, Porter NA, et al. Two distinct pathways of formation of 4-hydroxynonenal. Mechanisms of nonenzymatic transformation of the 9- and 13-hydroperoxides of linoleic acid to 4-hydroxyalkenals. J Biol Chem 2001; 276: 20831-8.
24. Yuan Q, Zhu X, Sayre LM. Chemical nature of stochastic generation of protein-based carbonyls: metal-catalyzed oxidation versus modification by products of lipid oxidation. Chem Res Toxicol 2007; 20: 129-30.
25. Medina-Navarro R, Duran-Reyes G, Hicks JJ. Identification on acrolein from the ozone oxidation of unsaturated fatty acids. Hum Exp Toxicol 1999; 18: 677-82.
26. Grimsrud PA, Xie H, Griffin TJ, et al. Oxidative stress and covalent modification of protein with bioactive aldehydes. J Biol Chem 2008; 283: 21837-41.
27. Medina-Navarro R, Guzmán-Grenfell AM, Díaz-Flores M, et al. Formation of an adduct between insulin and the lipoperoxidation product acrolein decreases both the hypoglycemic effect of the hormone in rat and glucose uptake in 3T3 adipocytes. Chem Res Toxicol 2007; 20: 1477-81.